Skip to main content
. 2022 Jan 11;6(1):339–357. doi: 10.1182/bloodadvances.2021004916

Figure 1.

Figure 1.

OS, LFS, CI of relapse, and CI of NRM comparing haploidentical HCT with posttransplant cyclophosphamide to matched sibling, 8/8 HLA-MUD, 7/8 HLA-MUD, or UCB HCT.